Cullinan Therapeutics, Inc.

CGEM Healthcare Biotechnology

In the quarter to June 2026, EPS grew 24.3% and free cash flow grew 33.7%, each against the same quarter a year earlier.

12.93 1.07 −7.64%
Market cap
$901.0M
P/E
0.0×
Fwd P/E
4.8×
Dividend yield
—
F-score
n/a
Altman Z
33.57
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
8.23 10.01 10.01 10.15
Current Ratio
8.42 10.28 10.25 10.45
Net Debt/EBITDA
5.85 6.56 6.85 5.99
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.71 0.93 0.75 0.73
Capex/Depreciation
0.00 0.00 (0.14) (0.48)
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.62) (0.76) (0.65) (0.62)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.62) (0.76) (0.65) (0.62)
Cash per Share
5.44 5.82 6.40 5.63
Shareholders Equity per Share
5.23 6.06 6.92 7.64
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
5.23 6.06 6.92 7.64
Free Cash Flow
(38.22) (46.04) (38.12) (36.91)
Working Capital
301.35 326.25 349.02 309.48
Capital Expenditures
— — (0.01) (0.04)
Net Current Asset Value
299.94 324.60 347.11 309.48
EV/EBIT
— — — —
Capex to Sales
— — 0.00 0.00
Other line items
Average Payables
3.09 2.96 1.26 1.92
Average Assets
442.06 491.33 535.10 568.69
Average Common Equity
406.95 459.01 499.53 539.62

Fold the line items

Columns are period end dates